Who is sponsoring NCT06934967?

NCT06934967 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT06934967?

Interventions in NCT06934967: LNP023.

What condition does NCT06934967 study?

NCT06934967 studies Paroxysmal Nocturnal Hemoglobinuria (PNH).

Is NCT06934967 still recruiting?

NCT06934967 is currently recruiting now. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT06934967

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Recruiting now Phase 3 Last updated 16 April 2026

What this trial tests

Phase 3 trial testing LNP023 in Paroxysmal Nocturnal Hemoglobinuria (PNH) in 12 participants. Currently enrolling.

Timeline

28 October 2025

Primary endpoint
19 November 2031

19 December 2031

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	28 October 2025
Primary completion	19 November 2031
Estimated completion	19 December 2031
Sites	13 locations across Italy, Colombia, Netherlands, Germany, United States, Brazil

Drugs / interventions tested

LNP023 — full drug profile →

Conditions studied

Paroxysmal Nocturnal Hemoglobinuria (PNH) — all drugs for Paroxysmal Nocturnal Hemoglobinuria (PNH) →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 2 to 18, any sex, with Paroxysmal Nocturnal Hemoglobinuria (PNH). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this open-label, single arm, multicenter, phase 3 study is to assess the pharmacokinetics of iptacopan in pediatric patients and to assess whether iptacopan is safe and well tolerated when used for the treatment of pediatric paroxysmal nocturnal hemoglobinuria (PNH) patients 2 to \< 18 years of age.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The varieties of therapeutic experience: navigating treatment options for patients with PNH.
Bienz M, Patriquin CJ. · · 2025 · PMID 41348037 · DOI 10.1182/hematology.2025000701

Verify or expand the search:

Other trials of LNP023

Trials testing the same drug.

NCT06931691 — A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China · recruiting
NCT04557462 — A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in P · Phase 3 · recruiting
NCT04558918 — Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antib · Phase 3 · completed
NCT04578834 — Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients · Phase 3 · completed
NCT04154787 — Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy · Phase 2 · terminated

Other recruiting trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Currently open trials in the same condition.

NCT07187401 — A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in · Phase 1, PHASE2 · recruiting
NCT07229235 — REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria · recruiting
NCT06312644 — Study of Ultomiris® (Ravulizumab) Safety in Pregnancy · recruiting
NCT06933914 — Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria · Phase 2, PHASE3 · recruiting
NCT05876312 — Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient · Phase 1, PHASE2 · active not recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06934967 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06934967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing